Varicella zoster virus: molecular controls of cell fusion-dependent pathogenesis

水痘带状疱疹病毒:细胞融合依赖性发病机制的分子控制

基本信息

  • 批准号:
    8401103
  • 负责人:
  • 金额:
    $ 39.27万
  • 依托单位:
  • 依托单位国家:
    美国
  • 项目类别:
  • 财政年份:
    2012
  • 资助国家:
    美国
  • 起止时间:
    2012-06-01 至 2017-05-31
  • 项目状态:
    已结题

项目摘要

DESCRIPTION (provided by applicant): Varicella-zoster virus (VZV) is a medically important human ¿-herpesvirus that causes varicella (chickenpox) and leads to zoster (shingles) upon reactivation from latently infected sensory ganglia. Varicella can be serious and is life-threatening in immunocompromised patients. VZV exhibits tropism for T cells, skin and neurons during infection of the human host and overcomes the usual constraint against fusion between fully differentiated host cells to form multinucleated polykaryocytes, a hallmark of VZV pathogenesis. Glycoprotein B (gB) along with the gH/gL heterodimer is known to be critical for fusion of the virion envelope with the target cell membrane during herpesvirus entry. Our novel concept is that VZV mediates cell-cell fusion through a gB-dependent intracellular signaling function. This is based on our new evidence that preventing tyrosine phosphorylation of the gB cytoplasmic domain (gBcyt) leads to anomalies in cell-cell fusion and syncytia formation in vitro. Our application will investigate how the gBcyt modulates cell- cell fusion mechanisms via intracellular signaling pathways to produce the characteristic syncytia in vitro and fusion of epidermal cells and neuron-satellite cells caused by VZV infection of skin and ganglia in vivo. In Aim 1 we will determine how VZV modifies cellular regulation to favor transcription of genes that facilitate cell-cell fusion and syncytia formation by applying the high-throughput whole-transcriptome sequencing technology, RNA-seq, to our new fusion assay and our virus mutants, which carry mutations in the gBcyt residues that affect cell-cell fusion. To quantify the effects o tyrosine phosphorylation, the spatiotemporal evolution of syncytia formation will be measured in real-time for VZV and the gBcyt mutants. To determine the role of genes in cell fusion, as identified by RNA-seq, we will perform gene perturbation experiments to assess their biological significance in the context of VZV replication. Aim 2 will determine how the gBcyt regulates intracellular signaling events in cell fusion via post-translational modifications of tyrosine and/r lysine residues by cellular or viral proteins. Mass spectrometry will be used to identify cellular and viral proteins that interact with the gBcyt domain in its tyrosine-phosphorylated and non-phosphorylated forms. Lysine mutagenesis studies will be performed to assess the effects of acetylation and ubiquitination posttranslational modifications on VZV fusion and virulence. Finally, Aim 3 will establish whether the gBcyt modulates polykaryocyte formation to optimize VZV infection of skin and DRG. Our mutant viruses will be compared to wild type VZV for replication competencies in human skin and neuronal tissue using novel reporter viruses. We will establish the role of newly identified genes required for cell-cell fusion using a novel shRNA carrying virus. Given the significance of polykaryocyte formation for pathogenesis, deciphering how VZV regulates this process has the potential to yield new strategies for vaccine virus attenuation and antiviral drug design to ease the burden on vulnerable populations. PUBLIC HEALTH RELEVANCE: Varicella-zoster virus (VZV) is a medically important human herpesvirus that causes chicken pox and shingles. These diseases can be serious, painful and life-threatening in immunocompromised patients. Drug treatments to prevent pain are ineffective and current vaccines are not recommended for the immunocompromised. A hall mark of VZV disease is the fusion of cells in human skin and neuronal tissue. We have strong evidence that molecular events inside cells infected with VZV are controlled by a protein, glycoprotein B, found on the surface of the virus. The goal of our research will be to provide a fundamental understanding of how VZV glycoprotein B triggers cells in human tissues to fuse and cause disease. These studies have great potential to provide common themes with other human herpesvirus viruses that will be directly relevant to developing safer vaccines and more effective drug treatments.
描述(由申请人提供):水痘带状疱疹病毒(VZV)是一种医学上重要的人类疱疹病毒,可引起水痘(水痘),并在潜伏感染的感觉神经节重新激活后导致带状疱疹(带状疱疹)。对于免疫功能低下的患者,水痘可能是严重的,并危及生命。在感染人类宿主期间,VZV表现出对T细胞、皮肤和神经元的趋向性,并克服了完全分化的宿主细胞之间融合形成多核多核细胞的通常限制,这是VZV发病机制的一个标志。糖蛋白B (gB)和gH/gL异源二聚体在疱疹病毒进入过程中对病毒粒子包膜与靶细胞膜融合至关重要。我们的新概念是,VZV通过依赖gb的细胞内信号功能介导细胞-细胞融合。这是基于我们的新证据,即阻止酪氨酸磷酸化的gB细胞质结构域(gBcyt)导致细胞-细胞融合和合胞体形成的异常。我们的应用将研究gBcyt如何通过细胞内信号通路调节细胞-细胞融合机制,在体外产生特征性合胞体,并在体内由VZV感染皮肤和神经节引起表皮细胞和神经元卫星细胞的融合。在Aim 1中,我们将通过将高通量全转录组测序技术RNA-seq应用于我们的新融合实验和我们的病毒突变体,确定VZV如何修改细胞调控,以促进促进细胞融合和合胞体形成的基因的转录。为了量化酪氨酸磷酸化的影响,将实时测量VZV和gBcyt突变体合胞体形成的时空演变。为了确定基因在细胞融合中的作用,正如RNA-seq所鉴定的那样,我们将进行基因扰动实验来评估它们在VZV复制背景下的生物学意义。目的2将确定gBcyt如何通过细胞或病毒蛋白对酪氨酸和/r赖氨酸残基的翻译后修饰来调节细胞融合中的细胞内信号事件。质谱法将用于鉴定与酪氨酸磷酸化和非磷酸化形式的gBcyt结构域相互作用的细胞和病毒蛋白。将进行赖氨酸诱变研究,以评估乙酰化和泛素化翻译后修饰对VZV融合和毒力的影响。最后,Aim 3将确定gBcyt是否调节多核细胞的形成以优化VZV感染皮肤和DRG。我们的突变病毒将与野生型VZV进行比较,用新的报告病毒在人类皮肤和神经组织中的复制能力。我们将利用一种新的shRNA来确定细胞-细胞融合所需的新鉴定基因的作用

项目成果

期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)

数据更新时间:{{ journalArticles.updateTime }}

{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

数据更新时间:{{ journalArticles.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ monograph.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ sciAawards.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ conferencePapers.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ patent.updateTime }}

Ann Arvin其他文献

Ann Arvin的其他文献

{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

{{ truncateString('Ann Arvin', 18)}}的其他基金

Varicella zoster virus: molecular controls of cell fusion-dependent pathogenesis
水痘带状疱疹病毒:细胞融合依赖性发病机制的分子控制
  • 批准号:
    8663185
  • 财政年份:
    2012
  • 资助金额:
    $ 39.27万
  • 项目类别:
Varicella zoster virus: molecular controls of cell fusion-dependent pathogenesis
水痘带状疱疹病毒:细胞融合依赖性发病机制的分子控制
  • 批准号:
    8472440
  • 财政年份:
    2012
  • 资助金额:
    $ 39.27万
  • 项目类别:
Protective Immunity Against Herpesvirus Infections
针对疱疹病毒感染的保护性免疫
  • 批准号:
    8260368
  • 财政年份:
    2011
  • 资助金额:
    $ 39.27万
  • 项目类别:
Varicella-zoster Virus: Tegument Proteins in Pathogenesis
水痘带状疱疹病毒:发病机制中的皮层蛋白
  • 批准号:
    8121089
  • 财政年份:
    2010
  • 资助金额:
    $ 39.27万
  • 项目类别:
Investigation of herpes simplex virus -1 neurotropism in SCID DRG xenografts
SCID DRG 异种移植物中单纯疱疹病毒-1 向神经性的研究
  • 批准号:
    7638379
  • 财政年份:
    2009
  • 资助金额:
    $ 39.27万
  • 项目类别:
Investigation of herpes simplex virus -1 neurotropism in SCID DRG xenografts
SCID DRG 异种移植物中单纯疱疹病毒-1 向神经性的研究
  • 批准号:
    7847594
  • 财政年份:
    2009
  • 资助金额:
    $ 39.27万
  • 项目类别:
CD8 T cell Immunity to Influenza
CD8 T 细胞对流感的免疫
  • 批准号:
    7657178
  • 财政年份:
    2008
  • 资助金额:
    $ 39.27万
  • 项目类别:
Pilot Projects Component (Pilot Proj 2: Guccione)
试点项目组件(试点项目 2:Guccione)
  • 批准号:
    7657168
  • 财政年份:
    2008
  • 资助金额:
    $ 39.27万
  • 项目类别:
Protective Immunity Against Herpesvirus Infections
针对疱疹病毒感染的保护性免疫力
  • 批准号:
    7212913
  • 财政年份:
    2007
  • 资助金额:
    $ 39.27万
  • 项目类别:
ANTIVIRAL IMMUNE MECHANISMS IN EARLY CHILDHOOD
幼儿期的抗病毒免疫机制
  • 批准号:
    7202035
  • 财政年份:
    2004
  • 资助金额:
    $ 39.27万
  • 项目类别:

相似海外基金

Rational design of rapidly translatable, highly antigenic and novel recombinant immunogens to address deficiencies of current snakebite treatments
合理设计可快速翻译、高抗原性和新型重组免疫原,以解决当前蛇咬伤治疗的缺陷
  • 批准号:
    MR/S03398X/2
  • 财政年份:
    2024
  • 资助金额:
    $ 39.27万
  • 项目类别:
    Fellowship
CAREER: FEAST (Food Ecosystems And circularity for Sustainable Transformation) framework to address Hidden Hunger
职业:FEAST(食品生态系统和可持续转型循环)框架解决隐性饥饿
  • 批准号:
    2338423
  • 财政年份:
    2024
  • 资助金额:
    $ 39.27万
  • 项目类别:
    Continuing Grant
Re-thinking drug nanocrystals as highly loaded vectors to address key unmet therapeutic challenges
重新思考药物纳米晶体作为高负载载体以解决关键的未满足的治疗挑战
  • 批准号:
    EP/Y001486/1
  • 财政年份:
    2024
  • 资助金额:
    $ 39.27万
  • 项目类别:
    Research Grant
Metrology to address ion suppression in multimodal mass spectrometry imaging with application in oncology
计量学解决多模态质谱成像中的离子抑制问题及其在肿瘤学中的应用
  • 批准号:
    MR/X03657X/1
  • 财政年份:
    2024
  • 资助金额:
    $ 39.27万
  • 项目类别:
    Fellowship
CRII: SHF: A Novel Address Translation Architecture for Virtualized Clouds
CRII:SHF:一种用于虚拟化云的新型地址转换架构
  • 批准号:
    2348066
  • 财政年份:
    2024
  • 资助金额:
    $ 39.27万
  • 项目类别:
    Standard Grant
The Abundance Project: Enhancing Cultural & Green Inclusion in Social Prescribing in Southwest London to Address Ethnic Inequalities in Mental Health
丰富项目:增强文化
  • 批准号:
    AH/Z505481/1
  • 财政年份:
    2024
  • 资助金额:
    $ 39.27万
  • 项目类别:
    Research Grant
ERAMET - Ecosystem for rapid adoption of modelling and simulation METhods to address regulatory needs in the development of orphan and paediatric medicines
ERAMET - 快速采用建模和模拟方法的生态系统,以满足孤儿药和儿科药物开发中的监管需求
  • 批准号:
    10107647
  • 财政年份:
    2024
  • 资助金额:
    $ 39.27万
  • 项目类别:
    EU-Funded
BIORETS: Convergence Research Experiences for Teachers in Synthetic and Systems Biology to Address Challenges in Food, Health, Energy, and Environment
BIORETS:合成和系统生物学教师的融合研究经验,以应对食品、健康、能源和环境方面的挑战
  • 批准号:
    2341402
  • 财政年份:
    2024
  • 资助金额:
    $ 39.27万
  • 项目类别:
    Standard Grant
Ecosystem for rapid adoption of modelling and simulation METhods to address regulatory needs in the development of orphan and paediatric medicines
快速采用建模和模拟方法的生态系统,以满足孤儿药和儿科药物开发中的监管需求
  • 批准号:
    10106221
  • 财政年份:
    2024
  • 资助金额:
    $ 39.27万
  • 项目类别:
    EU-Funded
Recite: Building Research by Communities to Address Inequities through Expression
背诵:社区开展研究,通过表达解决不平等问题
  • 批准号:
    AH/Z505341/1
  • 财政年份:
    2024
  • 资助金额:
    $ 39.27万
  • 项目类别:
    Research Grant
{{ showInfoDetail.title }}

作者:{{ showInfoDetail.author }}

知道了